Merger Pending
Boundless Bio and Serapha Bio merger
Announced 23 Jun 2026
Advisers
- Target
- Serapha Bio
- Acquirer
- Boundless Bio
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Leyden Labs acquisition of RIGImmune Sep 2026 · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Novo Nordisk stake in Orbis Medicines Sep 2026 · Biotech
- Eli Lilly and Company acquisition of Merida Biosciences Aug 2026 · US$2.9bn · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
Sources
- Jun 2026 Latham Watkins Advises Boundless Bio on Merger With Serapha Bio lw.com
- 23 Jun 2026 Press release (EX-99.1, exhibit), Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement sec.gov
- 25 Jun 2026 Gibson Dunn Advising Serapha Bio on Merger With Boundless Bio and $230 Million Private Financing gibsondunn.com


